Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?

Abstract New oral anticoagulation agents (NOACs) have definitively widened the existing spectrum of antithrombotic prophylaxis and therapy. NOACs (dabigatran etexilate, rivaroxaban, apixaban) can be given at fixed doses without coagulation monitoring. They show additional advantages in comparison with the mainly used vitamin K antagonists. Oral anticoagulation with NOACs has to be initiated and monitored carefully and patient- and disease-specific factors have to be taken into account. This article summarizes published clinical trial data related to dabigatran, apixaban and rivaroxaban. We will discuss special a…